These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 8759644

  • 1. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M, Golebiewski WM, Graham L, Turpin JA, Rice WG, Fliakas-Boltz V, Buckheit RW.
    J Med Chem; 1996 Aug 02; 39(16):3217-27. PubMed ID: 8759644
    [Abstract] [Full Text] [Related]

  • 2. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M, Casimiro-Garcia A, Hejchman E, Ruell JA, Huang M, Schaeffer CA, Williamson K, Rice WG, Buckheit RW.
    J Med Chem; 1998 Jun 04; 41(12):2076-89. PubMed ID: 9622549
    [Abstract] [Full Text] [Related]

  • 3. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
    Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E.
    J Mol Biol; 1994 Oct 28; 243(3):369-87. PubMed ID: 7525966
    [Abstract] [Full Text] [Related]

  • 4. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.
    Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Greco G, Novellino E, Altamura S, Di Renzo L.
    J Med Chem; 1996 Jul 05; 39(14):2672-80. PubMed ID: 8709096
    [Abstract] [Full Text] [Related]

  • 5. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB, Buckheit RW, Gulakowski RJ, Currens MJ, Vistica DT, Shoemaker RH, Stinson SF, Russell JD, Bader JP, Narayanan VL, Schultz RJ, Brouwer WG, Felauer EE, Boyd MR.
    J Pharmacol Exp Ther; 1996 Jan 05; 276(1):298-305. PubMed ID: 8558446
    [Abstract] [Full Text] [Related]

  • 6. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA, Kellam P, Kemp SD.
    Nature; 1993 Sep 30; 365(6445):451-3. PubMed ID: 7692302
    [Abstract] [Full Text] [Related]

  • 7. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
    Auwerx J, Stevens M, Van Rompay AR, Bird LE, Ren J, De Clercq E, Oberg B, Stammers DK, Karlsson A, Balzarini J.
    J Virol; 2004 Jul 30; 78(14):7427-37. PubMed ID: 15220416
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings.
    Deng BL, Cullen MD, Zhou Z, Hartman TL, Buckheit RW, Pannecouque C, De Clercq E, Fanwick PE, Cushman M.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2366-74. PubMed ID: 16321539
    [Abstract] [Full Text] [Related]

  • 9. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS, Fliakas-Boltz V, Bader JP, Buckheit RW.
    Leukemia; 1995 Oct 01; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
    Roth T, Morningstar ML, Boyer PL, Hughes SH, Buckheit RW, Michejda CJ.
    J Med Chem; 1997 Dec 19; 40(26):4199-207. PubMed ID: 9435891
    [Abstract] [Full Text] [Related]

  • 11. Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials.
    Artico M.
    Farmaco; 1996 May 19; 51(5):305-31. PubMed ID: 8767842
    [No Abstract] [Full Text] [Related]

  • 12. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W.
    Antivir Ther; 2004 Feb 19; 9(1):57-65. PubMed ID: 15040537
    [Abstract] [Full Text] [Related]

  • 13. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
    Fattorusso C, Gemma S, Butini S, Huleatt P, Catalanotti B, Persico M, De Angelis M, Fiorini I, Nacci V, Ramunno A, Rodriquez M, Greco G, Novellino E, Bergamini A, Marini S, Coletta M, Maga G, Spadari S, Campiani G.
    J Med Chem; 2005 Nov 17; 48(23):7153-65. PubMed ID: 16279773
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
    Silvestri MA, Nagarajan M, De Clercq E, Pannecouque C, Cushman M.
    J Med Chem; 2004 Jun 03; 47(12):3149-62. PubMed ID: 15163195
    [Abstract] [Full Text] [Related]

  • 15. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL, Imamichi T, Sarafianos SG, Arnold E, Hughes SH.
    J Virol; 2004 Sep 03; 78(18):9987-97. PubMed ID: 15331732
    [Abstract] [Full Text] [Related]

  • 16. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
    Buckheit RW, Fliakas-Boltz V, Yeagy-Bargo S, Weislow O, Mayers DL, Boyer PL, Hughes SH, Pan BC, Chu SH, Bader JP.
    Virology; 1995 Jun 20; 210(1):186-93. PubMed ID: 7540784
    [Abstract] [Full Text] [Related]

  • 17. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H, Aertsen A, Van Laethem K, Vandamme AM, De Clercq E, Pérez-Pérez MJ, San-Félix A, Velázquez S, Camarasa MJ, Balzarini J.
    Virology; 2001 Feb 01; 280(1):97-106. PubMed ID: 11162823
    [Abstract] [Full Text] [Related]

  • 18. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
    Balzarini J.
    Verh K Acad Geneeskd Belg; 1995 Feb 01; 57(6):575-600. PubMed ID: 8686372
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.
    Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, Parniak MA.
    Biochemistry; 1997 Mar 18; 36(11):3179-85. PubMed ID: 9115994
    [Abstract] [Full Text] [Related]

  • 20. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W, Matsuda M, Matsuda Z, Abumi H, Okano A, Oishi T, Moriya K, Yamamoto Y, Fukutake K, Mimaya J, Ajisawa A, Taki M, Yamada K, Nagai Y.
    J Hum Virol; 1999 Mar 18; 2(3):146-53. PubMed ID: 10413366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.